Strong clinical results, including significant reductions in liver fat, improvements in glycemic control, and fibrosis regression without worsening of NASH, support the efficacy and potential of EFX.

The prevalence of NASH in global populations continues to expand in conjunction with the ongoing obesity and diabetes epidemic. Over the next decade, the disease is projected to become the leading ...